NYSE:ADCT ADC Therapeutics (ADCT) Stock Forecast, Price & News $2.38 +0.03 (+1.28%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$2.31▼$2.5050-Day Range$1.90▼$2.6652-Week Range$1.85▼$10.88Volume195,716 shsAverage Volume576,970 shsMarket Capitalization$182.81 millionP/E RatioN/ADividend YieldN/APrice Target$10.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ADC Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside327.2% Upside$10.17 Price TargetShort InterestBearish9.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.73) to ($2.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector905th out of 1,980 stocksPharmaceutical Preparations Industry433rd out of 978 stocks 3.3 Analyst's Opinion Consensus RatingADC Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.17, ADC Therapeutics has a forecasted upside of 327.2% from its current price of $2.38.Amount of Analyst CoverageADC Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.79% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in ADC Therapeutics has recently decreased by 17.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADCT. Previous Next 2.9 News and Social Media Coverage News SentimentADC Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ADC Therapeutics this week, compared to 2 articles on an average week.Search Interest32 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.MarketBeat Follows4 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of ADC Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.56% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($2.73) to ($2.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADC Therapeutics has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ADC Therapeutics (NYSE:ADCT) StockADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Read More Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADCT Stock News HeadlinesJune 1, 2023 | finance.yahoo.comADC Therapeutics to Participate in the Jefferies Healthcare ConferenceMay 30, 2023 | americanbankingnews.comBrokerages Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $10.80June 2, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 30, 2023 | americanbankingnews.comADC Therapeutics SA (NYSE:ADCT) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 12, 2023 | msn.comRBC Capital Maintains Adc Telecommunications (ADCT) Outperform RecommendationMay 11, 2023 | finance.yahoo.comADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid CongressMay 11, 2023 | finance.yahoo.comThese Analysts Think ADC Therapeutics SA's (NYSE:ADCT) Sales Are Under ThreatMay 10, 2023 | finance.yahoo.comADC Therapeutics First Quarter 2023 Earnings: Misses ExpectationsJune 2, 2023 | Vector Vest (Ad)Free Stock Analysis Report: See The True Value of Any StockGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 10, 2023 | finance.yahoo.comADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 10, 2023 | americanbankingnews.comAnalysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $10.80May 9, 2023 | finance.yahoo.comADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2023 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy UpdateMay 9, 2023 | msn.comADC Therapeutics Non-GAAP EPS of -$0.53, revenue of $18.99M misses by $1.1MMay 9, 2023 | finance.yahoo.comADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy UpdateMay 8, 2023 | americanbankingnews.comADC Therapeutics (ADCT) Scheduled to Post Earnings on TuesdayMay 2, 2023 | finance.yahoo.comXenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?May 2, 2023 | finance.yahoo.comADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023April 26, 2023 | americanbankingnews.comADC Therapeutics (NYSE:ADCT) Downgraded by Bank of America to "Underperform"April 25, 2023 | msn.comB of A Securities Downgrades Adc Telecommunications (ADCT)April 17, 2023 | finance.yahoo.comADC Therapeutics SA (NYSE:ADCT) is definitely on the radar of institutional investors who own 34% of the companyApril 15, 2023 | americanbankingnews.comADC Therapeutics SA (NYSE:ADCT) Receives $10.17 Average PT from AnalystsApril 7, 2023 | markets.businessinsider.comADC Therapeutics (ADCT) Receives a Buy from RBC CapitalApril 5, 2023 | americanbankingnews.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Grows By 5.3%March 22, 2023 | finance.yahoo.comSeres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?March 15, 2023 | finance.yahoo.comADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022March 8, 2023 | finance.yahoo.comBioMarin (BMRN) Provides FDA Filing Update for Gene TherapiesSee More Headlines ADCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADCT Company Calendar Last Earnings11/02/2021Today6/01/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ADCT CUSIPN/A CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees312Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.17 High Stock Price Forecast$20.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+327.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-155,800,000.00 Net Margins-108.86% Pretax Margin-107.74% Return on Equity-229.20% Return on Assets-38.76% Debt Debt-to-Equity Ratio2.57 Current Ratio4.69 Quick Ratio4.46 Sales & Book Value Annual Sales$209.91 million Price / Sales0.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book4.86Miscellaneous Outstanding Shares76,810,000Free Float49,619,000Market Cap$182.81 million OptionableNot Optionable Beta1.10 Key ExecutivesDr. Ameet Mallik M.B.A. (Age 51)M.S., CEO & Director Dr. Christopher J. Martin DPHIL (Age 64)Ph.D., Co-Founder & Non-Exec. Director Mr. Jose I. Carmona M.B.A. (Age 51)Chief Financial Officer Dr. Michael Mulkerrin Ph.D.Chief Technical Operations OfficerDr. Patrick van Berkel Ph.D. (Age 55)Chief Scientific Officer Amanda HamiltonInvestor Relations OfficerMs. Susan Romanus (Age 58)Chief Compliance & Quality Officer Mr. Peter J. Graham Esq. (Age 56)Chief Legal Officer Ms. Kimberly Pope (Age 57)Sr. VP & Chief People Officer Dr. Joseph Camardo Ph.D. (Age 70)Chief Medical Officer More ExecutivesKey CompetitorsZevra TherapeuticsNASDAQ:ZVRACitius PharmaceuticalsNASDAQ:CTXRKinnate BiopharmaNASDAQ:KNTESilence TherapeuticsNASDAQ:SLNSelecta BiosciencesNASDAQ:SELBView All CompetitorsInstitutional OwnershipAmeriprise Financial Inc.Bought 34,236 shares on 5/22/2023Ownership: 0.147%JPMorgan Chase & Co.Bought 87,348 shares on 5/18/2023Ownership: 4.025%Squarepoint Ops LLCBought 104,547 shares on 5/16/2023Ownership: 0.136%Susquehanna International Group LLPBought 12,065 shares on 5/16/2023Ownership: 0.034%Jane Street Group LLCBought 25,584 shares on 5/16/2023Ownership: 0.033%View All Institutional Transactions ADCT Stock - Frequently Asked Questions Should I buy or sell ADC Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADCT shares. View ADCT analyst ratings or view top-rated stocks. What is ADC Therapeutics' stock price forecast for 2023? 6 brokers have issued twelve-month price targets for ADC Therapeutics' stock. Their ADCT share price forecasts range from $5.00 to $20.00. On average, they expect the company's share price to reach $10.17 in the next year. This suggests a possible upside of 327.2% from the stock's current price. View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts. How have ADCT shares performed in 2023? ADC Therapeutics' stock was trading at $3.84 at the start of the year. Since then, ADCT shares have decreased by 38.0% and is now trading at $2.38. View the best growth stocks for 2023 here. Are investors shorting ADC Therapeutics? ADC Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 6,160,000 shares, a decline of 17.1% from the April 30th total of 7,430,000 shares. Based on an average daily trading volume, of 611,200 shares, the days-to-cover ratio is currently 10.1 days. Approximately 9.8% of the company's shares are short sold. View ADC Therapeutics' Short Interest. When is ADC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our ADCT earnings forecast. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) released its earnings results on Tuesday, November, 2nd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.01. The company had revenue of $13.15 million for the quarter, compared to analyst estimates of $7.74 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 229.20% and a negative net margin of 108.86%. During the same period last year, the company posted ($0.29) earnings per share. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), Raytheon Technologies (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX). When did ADC Therapeutics IPO? (ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO. What is ADC Therapeutics' stock symbol? ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT." Who are ADC Therapeutics' major shareholders? ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Prosight Management LP (4.24%), JPMorgan Chase & Co. (4.03%), Sio Capital Management LLC (2.81%), Bank of America Corp DE (2.14%), Perceptive Advisors LLC (1.95%) and Pictet Asset Management SA (1.78%). How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ADC Therapeutics' stock price today? One share of ADCT stock can currently be purchased for approximately $2.38. How much money does ADC Therapeutics make? ADC Therapeutics (NYSE:ADCT) has a market capitalization of $182.81 million and generates $209.91 million in revenue each year. The company earns $-155,800,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. How many employees does ADC Therapeutics have? The company employs 312 workers across the globe. How can I contact ADC Therapeutics? The official website for the company is www.adctherapeutics.com. The company can be reached via phone at 41-21-653-0200 or via email at amanda.hamilton@adctherapeutics.com. This page (NYSE:ADCT) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.